ACECARD

Acecard effects:
• Antiaggregant effect:
• inhibition of both isoenzymes of cyclooxygenase (COX-1 and COX-2) in platelets, which blocks the synthesis of thromboxane A2 and suppresses platelet aggregation.
• inhibition of biosynthesisantiaggregational (antithrombogenic) prostaglandin-prostacyclin (PGI2) and other antithrombotic prostaglandins (PGE1, PGD2, etc.).
• Promotes the release of prostacyclin from the endothelium of blood vessels, and has a depressing effect on the release and activation of platelet factors III and IV.

• Prevention of acute myocardial infarction in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, hypertension, obesity, smoking, elderly age) and repeated myocardial infarction.
• Unstable angina.
• Prevention of ischemic stroke (including in patients with transient impairment of cerebral circulation).
• Preventing thromboembolism after surgery and invasive vascular interventions (eg, coronary artery bypass grafting, carotid endarterectomy, arteriovenous shunting, angioplasty and stenting of the coronary arteries, carotid angioplasty).
• Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (including, with prolonged immobilization as a result of extensive surgical intervention).